Adamis Pharmaceuticals Corporation announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 16.527 million compared to USD 22.113 million a year ago. Operating loss was USD 49.778 million compared to USD 29.350 million a year ago. Net loss was USD 49.391 million compared to USD 27.512 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 0.52 a year ago.